|
| Drug class | Drug | Citation | Model | Summary of key findings |
|
|
GLP-1 analogue | Liraglutide |
Fujita et al., 2014 [66] | STZ in male rats ± 0.6 mg/kg/day for 4 weeks | Inhibition of albuminuria in combination with reduced oxidative stress and fibrosis |
| Liraglutide |
Ojima et al., 2013 [68] | KK/Ta Akita male mice, 200 ug/kg/day for 4 weeks from 8 to 12 weeks | Adenylate cyclase dependent decrease in albuminuria, histopathological changes, and oxidative stress |
|
GLP-1 receptor
agonists | Exendin-4 |
Kodera et al., 2011 [69] | STZ in male rats ± continuous infusion of 0.5 ug/kg for 2 weeks | Inhibition of albuminuria in combination with reduced oxidative stress and histopathological changes |
| Exendin-4 |
Park et al., 2007 [70] | STZ in male rats ± 10 ug/kg/day for 4 weeks | Reduced albuminuria and hyperfiltration in association with reduced histopathological change and attenuated inflammation, oxidative stress, and fibrosis |
| Exendin-4 |
Liu et al., 2012 [71] | db/db male mice ± 0.5 or 1 nmol/kg/day for 8 weeks from 8 to 16 weeks | Reduced albuminuria in association with attenuated histopathological change, inflammation, and oxidative stress |
|
| DPP-IV inhibitors | PKF-275-055 |
Alter et al., 2012 [73] | STZ in male rats ± 4 mg/kg/day for 8 weeks | Reduced albuminuria in association with improved histopathology and evidence of anti-inflammatory effect |
| NWT-03 egg protein hydrolysate |
Mega et al., 2011 [74] | Male ZDF rats ± 1 g/kg/day for 15 weeks from 10 to 25 weeks | Reduced albuminuria, oxidative stress, and glomerulosclerosis |
| Sitagliptin |
Kawasaki et al., 2014 [76] | Male ZDF rats ± 10 mg/kg/day for 6 weeks from 20 to 26 weeks | Reduced uraemia and glomerulosclerosis |
| Vildagliptin |
Kodera et al., 2014 [72] | STZ in male rats ± 4 or 8 mg/kg/day for 24 weeks | Reduced albuminuria, improved creatinine clearance, and less evidence of glomerular and interstitial fibrosis |
| Linagliptin |
Wang et al., 2012 [75] | STZ in male eNOS KO mice ± 3 mg/kg/day for 12 weeks | Reduced albuminuria and glomerulosclerosis when in combination with an angiotensin receptor blocker |
|
